Glucose-lowering and hypolipidemic activities of polysaccharides from Cordyceps taii in streptozotocin-induced diabetic mice.

BMC Complement Altern Med

Zunyi Municipal Key Laboratory of Medicinal Biotechnology, Center for Translational Medicine, Affiliated Hospital of Zunyi Medical University, 149 Dalian Road, Zunyi, 563003, People's Republic of China.

Published: August 2019

Background: Hyperglycemia and dyslipidemia are classic features of patients with diabetes mellitus (DM). Cordyceps taii, a folk medicinal fungus native to southern China, possesses various pharmacological activities. This study aimed to assess the glucose-lowering and hypolipidemic effects of polysaccharides from C. taii (CTP) in streptozotocin (STZ)-induced diabetic mice.

Methods: Kunming mice were intraperitoneally injected with STZ at a dose of 100 mg/kg body weight. After induction of diabetes, diabetic mice were randomly divided into five groups: diabetic mellitus group (DM), metformin-treated group, low, medium, and high-dose CTP-treated group (CTP-L, CTP-M, and CTP-H). Normal mice served as the control group. After treatment for 28 days, body weight, fasting serum insulin (FSI), fasting blood glucose (FBG), homeostasis model assessment-insulin resistance (HOMA-IR), triglyceride (TG), total cholesterol (TC), low-density lipoprotein-cholesterol (LDL-C), high-density lipoprotein-cholesterol (HDL-C), tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and C-reactive protein (CRP) levels were measured. Histological analysis of pancreatic tissue and immune organ indices was also performed to evaluate the anti-diabetes effect of CTP. SPSS (version 21.0) software was used for statistical analysis, and statistical differences were considered significant at p < 0.05.

Results: Compared with the DM group, the body weight and FSI level of CTP-H group increased by 36.13 and 32.47%, whereas the FBG and HOMA-IR decreased by 56.79 and 42.78%, respectively (p < 0.05). Histopathological examination of the pancreas revealed that CTP improved and repaired the impaired islet β-cells in pancreatic tissue. Compared with the DM group, the levels of TC, TG, and LDL-C decreased by 13.84, 31.87, and 36.61%, whereas that of HDL-C increased by 28.60% in CTP-H (p < 0.05). Further study showed that the thymus index in CTP-H was elevated by approximately 54.96%, and the secretion of pro-inflammatory cytokines TNF-α, IL-6, and CRP was inhibited by approximately 19.97, 34.46, and 35.41%, respectively (p < 0.05).

Conclusion: The anti-diabetes effect of CTP is closely associated with immunoregulation and anti-inflammation, and CTP may be considered as a therapeutic drug or functional food for DM intervention.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6708201PMC
http://dx.doi.org/10.1186/s12906-019-2646-xDOI Listing

Publication Analysis

Top Keywords

glucose-lowering hypolipidemic
8
cordyceps taii
8
diabetic mice
8
body weight
8
hypolipidemic activities
4
activities polysaccharides
4
polysaccharides cordyceps
4
taii streptozotocin-induced
4
diabetic
4
streptozotocin-induced diabetic
4

Similar Publications

Objective: To evaluate the management in Victorian general practice of people who have been hospitalised with stroke or transient ischaemic attacks (TIA).

Study Design: Retrospective observational study; analysis of linked Australian Stroke Clinical Registry (AuSCR) and general practice data.

Setting: 383 general practices in the Eastern Melbourne, South Eastern Melbourne, and Gippsland primary health networks (Victoria), 1 January 2014 - 31 December 2018.

View Article and Find Full Text PDF
Article Synopsis
  • A systematic review and meta-analysis was conducted to determine if baseline use of statins affects the cardiovascular and kidney benefits of two diabetes medications: SGLT-2 inhibitors and GLP-1 receptor agonists.
  • The analysis included 25 studies, revealing that both SGLT-2is and GLP-1RAs provided similar benefits in reducing cardiovascular and kidney risks in patients with type 2 diabetes, regardless of whether they were statin users or non-users.
  • The findings suggest that statin use does not significantly impact the effectiveness of these medications in improving cardiovascular and kidney outcomes for patients with type 2 diabetes.
View Article and Find Full Text PDF

Trends in the Use of Medications for Secondary Ischemic Stroke Prevention in Denmark, 2005-2021.

Neurology

May 2024

From the Departments of Clinical Epidemiology and Clinical Medicine (N.S., K.L., H.T.S.), Aarhus University; Department of Clinical Biochemistry (K.L.), Aarhus University Hospital, Denmark; Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine (J.C.L., E.P.), Brigham and Women's Hospital and Harvard Medical School, Boston, MA; and Yale School of Medicine (L.H.S.), New Haven, CT.

Background And Objectives: Understanding trends in the use of medications for secondary stroke prevention is crucial for identifying areas for improvement in stroke care. We examined the use of lipid-lowering, antihypertensive, glucose-lowering, oral anticoagulant, and antiplatelet medications after ischemic stroke hospitalization, from 2005 to 2021.

Methods: Using nationwide registries in Denmark, we identified a cohort of patients discharged from hospital with a first-time or recurrent ischemic stroke (N = 150,744).

View Article and Find Full Text PDF

Discontinuation of blood pressure-lowering, glucose-lowering, and lipid-lowering medications after bariatric surgery in patients with morbid obesity: a nationwide cohort study in South Korea.

Surg Obes Relat Dis

September 2024

BK21 FOUR Community-Based Intelligent Novel Drug Discovery Education Unit, College of Pharmacy and Research Institute of Pharmaceutical Sciences, Kyungpook National University, Daegu, South Korea. Electronic address:

Background: Limited evidence exists on the patterns of medication use for hypertension, diabetes mellitus (DM), and dyslipidemia after bariatric surgery among Asian patients.

Objectives: To investigate the patterns in the use of blood pressure-lowering, glucose-lowering, and lipid-lowering medications following BS in Korean patients with morbid obesity.

Setting: This study is a retrospective cohort study using the Health Insurance Review and Assignment claims database of South Korea (from 2019 to 2021).

View Article and Find Full Text PDF
Article Synopsis
  • - The study investigates the potential blood glucose-lowering effects of the leaf extract from an evergreen tree found in Ethiopia, which is traditionally used to treat diabetes, specifically observing its effects on diabetic mice.
  • - Various dosages (100, 200, and 400 mg/kg) of the leaf extract were tested in different mouse models, assessing both blood glucose levels and lipid profiles, with statistical significance calculated using one-way ANOVA.
  • - Results indicated the extract significantly reduced blood glucose levels in treated mice, with a notable reduction of up to 47.3% in the STZ-induced model, and showed no acute toxicity at doses up to 2 g/kg.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!